(Reuters) - Biogen Inc's second-quarter profit blew past estimates, driven by higher-than-expected demand for its recently approved spinal muscular atrophy (SMA) drug, Spinraza.
Reuters: Business News, Reuters: Business
Tue, 07/25/2017 - 4:06am
(Reuters) - Biogen Inc's second-quarter profit blew past estimates, driven by higher-than-expected demand for its recently approved spinal muscular atrophy (SMA) drug, Spinraza.